Slevin, I agree of course that our CVD patents "protect" us from direct and obvious infringement but that is what's actually happening because of the skinny label carve out of our Trigs indication. So regardless of what we call our drug..... it is still Icosaphant Ethyl.....which is what the generics have approval to produce and sell. This brings me back to what an AG would do for us ( we already have approval I believe to produce but just haven't pulled the trigger). The only benefits I see would be to further dilute the volume sold by the other generics and also provide a way for us to use up the IPE raw material's we've purchased and possibly negotiate better pricing if our V+generic V also succeeds in more volume sales.
Market Data 
Markets 
AI
